Weekly shot shows promise for major weight loss in obesity trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI ≥30 kg/m², OR BMI ≥27 kg/m² with ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease) * History of at least one unsuccessful dietary effort to lose weight (self-reported) * Investigator judges participant capable and willing to self-inject (or have assistance), follow lifestyle advice, maintain a diary, and complete questionnaires * Age ≥18 years * Meets protocol contraception/pregnancy criteria (as applicable) and provides written informed consent Exclusion Criteria: * Type 1 or type 2 diabetes, history of ketoacidosis/hyperosmolar state, or screening labs diagnostic of diabetes * Recent significant weight change (\>5 kg within 3 months prior to screening) * Prior/planned bariatric surgery; recent/ongoing endoscopic or device-based obesity therapies * Severe renal impairment (eGFR \<30 mL/min/1.73 m²) * Clinically significant gastric emptying abnormality or chronic use of drugs that directly affect GI motility * History of chronic or acute pancreatitis * Clinically significant thyroid abnormalities at screening (e.g., TSH outside protocol range) or anticipated need to initiate thyroid replacement during study * Obesity due to other endocrinologic disorders (e.g., Cushing syndrome) or monogenic/syndromic obesity (e.g., MC4R deficiency, Prader-Willi syndrome) * Significant unstable major depressive disorder/severe psychiatric disorder, lifetime suicide attempt, or concerning suicidality screening (PHQ-9/C-SSRS criteria) * Uncontrolled hypertension; recent major cardiovascular events; NYHA class IV heart failure * Active or significant liver disease or certain elevated liver tests at screening (per protocol thresholds) * Elevated calcitonin above protocol thresholds; personal/family history of medullary thyroid carcinoma or MEN2 * Active/untreated malignancy or remission \<5 years (with specified exceptions) * Any other condition contraindicating GLP-1 receptor agonist therapy